Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia.

Kellner, Christian; Peipp, Matthias; Gramatzki, Martin; Schrappe, Martin; Schewe, Denis M

Kellner, Christian; Peipp, Matthias; Gramatzki, Martin; Schrappe, Martin; Schewe, Denis M.

Afiliação

Kellner C; Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Peipp M; Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Gramatzki M; Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Schrappe M; Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Schewe DM; Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany.

Oncoimmunology ; 7(8): e1448331, 2018.

Article em En | MEDLINE | ID: mdl-30221037

Palavras-chave

Acute lymphoblastic leukemia; CAR T cells; CD19; Fc engineering; bispecific antibodies

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google